{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:58:20Z","timestamp":1770188300333,"version":"3.49.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vedolizumab binds to \u03b14\u03b27 integrin, thereby inhibiting lymphocyte migration into the gastrointestinal tract. It is used to treat moderate to severe ulcerative colitis (UC) and Crohn\u2019s disease. This study evaluated vedolizumab concentrations, \u03b14\u03b27 integrin saturation, and T lymphocyte immunophenotype proportions in blood, serum and inflamed colorectal tissue according to treatment efficacy in patients with moderate to severe UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a phase 4, multicenter, open-label, single-arm study. Patients were observed for a total of 54 weeks. Clinical remission was defined as complete Mayo score\u2009\u2264\u20092 or partial Mayo score\u2009\u2264\u20091.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 11 patients with UC, 10 of whom were tumor necrosis factor alpha antagonist therapy-na\u00efve. Seven and six patients were in remission at weeks 14 and 54, respectively. Vedolizumab concentrations and lymphocyte \u03b14\u03b27 integrin saturation in serum and inflamed colorectal tissue at weeks 14 and 54 did not differ significantly between remitters and non-remitters. The proportion of T cell subsets differed in remitters and non-remitters for CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells in blood at week 14 (62.7% vs 47.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0061) and CD161\n                      <jats:sup>+<\/jats:sup>\n                      memory CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells (65.7% vs 53.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0357) in inflamed colorectal tissue at week 54. Week 54 remitters had higher proportions of CD161\n                      <jats:sup>+<\/jats:sup>\n                      memory CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells in inflamed colorectal tissue at baseline (before vedolizumab treatment) than did week 54 non-remitters (48.5% vs 31.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0303).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>T cell immunophenotype may be a promising predictive biomarker of vedolizumab treatment efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0340271","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:28:41Z","timestamp":1770143321000},"page":"e0340271","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of tissue lymphocyte immunophenotype and clinical outcomes: A prospective study in patients with ulcerative colitis treated with vedolizumab"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-5488","authenticated-orcid":true,"given":"Katsuyoshi","family":"Ando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Sakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-8502","authenticated-orcid":true,"given":"Atsuo","family":"Maemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-4840","authenticated-orcid":true,"given":"Takahiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Taruishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Hamagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0322-4507","authenticated-orcid":true,"given":"Kaori","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4321-7774","authenticated-orcid":true,"given":"Mikihiro","family":"Fujiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"2","key":"pone.0340271.ref001","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: Innate immune system","volume":"24","author":"A Saez","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"pone.0340271.ref002","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.3390\/ijms24032696","article-title":"CD4 T-cell subsets and the pathophysiology of inflammatory bowel disease","volume":"24","author":"R Gomez-Bris","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"pone.0340271.ref003","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4161\/mabs.26392","article-title":"In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes","volume":"5","author":"T Wyant","year":"2013","journal-title":"MAbs"},{"issue":"11","key":"pone.0340271.ref004","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab","volume":"56","author":"M Rosario","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"pone.0340271.ref005","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"T Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"3","key":"pone.0340271.ref006","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"D Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"pone.0340271.ref007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"BG Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0340271.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212989","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"S Motoya","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"pone.0340271.ref009","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn\u2019s disease","volume":"11","author":"M Rosario","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"8","key":"pone.0340271.ref010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/ecco-jcc\/jjx033","article-title":"Blocking \u03b14\u03b27 integrin through vedolizumab: necessary but not sufficient?","volume":"11","author":"E Dreesen","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"11","key":"pone.0340271.ref011","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ibd\/izab053","article-title":"Vedolizumab tissue concentration correlates to mucosal inflammation and objective treatment response in inflammatory bowel disease","volume":"27","author":"RWM Pauwels","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"pone.0340271.ref012","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"E Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"pone.0340271.ref013","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/2050640619873784","article-title":"Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease","volume":"7","author":"L Guidi","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"8","key":"pone.0340271.ref014","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ecco-jcc\/jjz041","article-title":"Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease","volume":"13","author":"RC Ungaro","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"11","key":"pone.0340271.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months","volume":"15","author":"N Williet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"pone.0340271.ref016","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/apt.14548","article-title":"Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: A multicentre prospective observational study","volume":"47","author":"W Yacoub","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"pone.0340271.ref017","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ecco-jcc\/jjaa239","article-title":"Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations","volume":"15","author":"N Van den Berghe","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"3","key":"pone.0340271.ref018","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/apt.16937","article-title":"Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study","volume":"56","author":"N Vande Casteele","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"pone.0340271.ref019","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ecco-jcc\/jjaa178","article-title":"Dissecting common and unique effects of anti-\u03b14\u03b27 and anti-tumor necrosis factor treatment in ulcerative colitis","volume":"15","author":"M Veny","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"8","key":"pone.0340271.ref020","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1084\/jem.20080397","article-title":"Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor","volume":"205","author":"L Cosmi","year":"2008","journal-title":"J Exp Med"},{"issue":"3","key":"pone.0340271.ref021","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1084\/jem.20081712","article-title":"Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation","volume":"206","author":"MA Kleinschek","year":"2009","journal-title":"J Exp Med"},{"issue":"1","key":"pone.0340271.ref022","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2204269120","article-title":"Identification of a unique subset of tissue-resident memory CD4+ T cells in Crohn\u2019s disease","volume":"120","author":"T Yokoi","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"pone.0340271.ref023","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1084\/jem.20190414","article-title":"Resident memory CD8 T cells persist for years in human small intestine","volume":"216","author":"R Bartolom\u00e9-Casado","year":"2019","journal-title":"J Exp Med"},{"issue":"2","key":"pone.0340271.ref024","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41385-020-0315-5","article-title":"CD4+ T cells persist for years in the human small intestine and display a TH1 cytokine profile","volume":"14","author":"R Bartolom\u00e9-Casado","year":"2021","journal-title":"Mucosal Immunol"},{"issue":"3","key":"pone.0340271.ref025","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13090","article-title":"Immunobiology and conflicting roles of the human CD161 receptor in T cells","volume":"94","author":"\u0141 Wyro\u017cemski","year":"2021","journal-title":"Scand J Immunol"},{"issue":"9","key":"pone.0340271.ref026","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/eji.1830270932","article-title":"Phenotypic and functional analysis of CD4 NKRP1A human T lymphocytes. Direct evidence that the NKRP1A molecule is involved in transendothelial migration","volume":"27","author":"A Poggi","year":"1997","journal-title":"Eur J Immunol"},{"issue":"1","key":"pone.0340271.ref027","doi-asserted-by":"crossref","first-page":"20262","DOI":"10.1038\/s41598-023-47618-3","article-title":"Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis","volume":"13","author":"H Miyazaki","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0340271.ref028","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41467-024-45665-6","article-title":"Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis","volume":"15","author":"E Mennillo","year":"2024","journal-title":"Nat Commun"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:28:47Z","timestamp":1770143327000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340271"}},"subtitle":[],"editor":[{"given":"Senthilnathan","family":"Palaniyandi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340271","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}